Sona Nanotech Inc
CNSX:SONA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Sona Nanotech Inc
Sona Nanotech, Inc. is a nanotechnology life sciences company, which engages in the development and manufacture of rod-shaped gold nanoparticles. The company is headquartered in Halifax, Nova Scotia and currently employs 8 full-time employees. The company went IPO on 2018-10-04. The firm is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its core technology is a rod-shaped nanoparticle manufactured at scale with surfactants that allow the production of two different product lines (Gemini and Omni) for use in both in-vitro and in-vivo applications, such as lateral flow diagnostics and cell imaging respectively. The firm's gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The firm also offers development services to help lateral flow producers create new lateral flow tests and improve existing tests for their product iteration.
Sona Nanotech, Inc. is a nanotechnology life sciences company, which engages in the development and manufacture of rod-shaped gold nanoparticles. The company is headquartered in Halifax, Nova Scotia and currently employs 8 full-time employees. The company went IPO on 2018-10-04. The firm is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its core technology is a rod-shaped nanoparticle manufactured at scale with surfactants that allow the production of two different product lines (Gemini and Omni) for use in both in-vitro and in-vivo applications, such as lateral flow diagnostics and cell imaging respectively. The firm's gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The firm also offers development services to help lateral flow producers create new lateral flow tests and improve existing tests for their product iteration.
